Dr. Al B. Benson
Claim this profileNorthwestern University
Area of expertise
Rectal Cancer
Al B. Benson has run 2 trials for Rectal Cancer. Some of their research focus areas include:
Colon Cancer
Al B. Benson has run 2 trials for Colon Cancer. Some of their research focus areas include:
Affiliated Hospitals
Northwestern University
Northwestern Medicine Lake Forest Hospital
Clinical Trials Al B. Benson is currently running
Preoperative Chemotherapy + Surgery
for Sarcoma
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.
Recruiting
2 awards
Phase 3
5 criteria
Radioactive Drug vs Everolimus
for Neuroendocrine Cancer
This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with everolimus, sunitinib, or cabozantinib in patients who have previously received 177Lu-DOTATATE for gastroenteropancreatic neuroendocrine tumor (GEPNET) that has spread from where it first started (primary site) to other places in the body (metastatic) and that cannot be removed by surgery (unresectable). PRRT is a type of radiation therapy for which a radioactive chemical is linked to a peptide (small protein) that targets tumor cells. When this radioactive peptide is injected into the body, it binds to a specific receptor found on some tumor cells. The radioactive peptide builds up in these cells and helps kill the tumor cells without harming normal cells. In this trial 177Lu-DOTATATE is used for PRRT. 177Lu-DOTATATE PRRT may increase the length of time until worsening of the GEPNET compared to the usual approach. Everolimus is in a class of medications called kinase inhibitors. It is also a type of angiogenesis inhibitor. Everolimus works by stopping tumor cells from reproducing and by decreasing blood supply to the tumor cells. Sunitinib and cabozantinib, block certain proteins, which may help keep tumor cells from growing. They may also prevent the growth of new blood vessels that tumors need to grow. Sunitinib malate is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Retreating with 177Lu-DOTATATE may work better than everolimus, sunitinib or cabozantinib in shrinking or stabilizing tumors in patients with metastatic and unresectable GEPNET who were previously treated with 177Lu-DOTATATE.
Recruiting
1 award
Phase 2
More about Al B. Benson
Clinical Trial Related
2 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Al B. Benson has experience with
- Lutetium Lu 177 Dotatate
- Oxaliplatin
- Preoperative Chemotherapy
- Surgery
- Trastuzumab
- Pertuzumab
Breakdown of trials Al B. Benson has run
Rectal Cancer
Colon Cancer
Retroperitoneal Sarcoma
Leiomyosarcoma
Uterine Leiomyosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Al B. Benson specialize in?
Al B. Benson focuses on Rectal Cancer and Colon Cancer. In particular, much of their work with Rectal Cancer has involved Stage III patients, or patients who are Stage IV.
Is Al B. Benson currently recruiting for clinical trials?
Yes, Al B. Benson is currently recruiting for 2 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Al B. Benson has studied deeply?
Yes, Al B. Benson has studied treatments such as Lutetium Lu 177 Dotatate, Oxaliplatin, Preoperative chemotherapy.
What is the best way to schedule an appointment with Al B. Benson?
Apply for one of the trials that Al B. Benson is conducting.
What is the office address of Al B. Benson?
The office of Al B. Benson is located at: Northwestern University, Chicago, Illinois 60611 United States. This is the address for their practice at the Northwestern University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.